title: Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores.
abstract: BACKGROUND
  The oncofetal protein insulin-like growth factor II mRNA binding protein 3 (IMP3) is an important factor for cell-migration and adhesion in malignancies. Recent studies have shown a remarkable overexpression of IMP3 in different human malignant neoplasms and also revealed it as an important prognostic marker in some tumor entities. To our knowledge, IMP3 expression has not been investigated in prostate carcinomas so far.
  
  
  METHODS
  Immunohistochemical stainings for IMP3 were performed on tissue microarray (TMA) organized samples from 507 patients: 31 normal prostate tissues, 425 primary carcinomas and 51 prostate cancer metastases or castration-resistant prostate cancers (CRPC). IMP3 immunoreactivity was semiquantitatively scored and correlated with clinical-pathologic parameters including survival.
  
  
  RESULTS
  IMP3 is significantly stronger expressed in prostate carcinomas compared to normal prostate tissues (p < 0.0001), but did not show significant correlation with the pT-stage, the proliferation index (MIB1), preoperative serum PSA level and the margin status. Only a weak and slightly significant correlation was found with the Gleason score and IMP3 expression failed to show prognostic significance in clinico-pathological correlation-analyses.
  
  
  CONCLUSIONS
  Although IMP3 is overexpressed in a significant proportion of prostate cancer cases, which might be of importance for novel therapeutic approaches, it does not appear to possess any immediate diagnostic or prognostic value, limiting its potential as a tissue biomarker for prostate cancer. These results might be corroborated by the fact, that two independent tumor cohorts were separately reviewed.
authors.affiliation: Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland.
authors.forename: Kristian
authors.initials: K
authors.lastname: Ikenberg
authors.forename: Florian R
authors.initials: FR
authors.lastname: Fritzsche
authors.forename: Ursina
authors.initials: U
authors.lastname: Zuerrer-Haerdi
authors.forename: Irina
authors.initials: I
authors.lastname: Hofmann
authors.forename: Thomas
authors.initials: T
authors.lastname: Hermanns
authors.forename: Helge
authors.initials: H
authors.lastname: Seifert
authors.forename: Michael
authors.initials: M
authors.lastname: Müntener
authors.forename: Maurizio
authors.initials: M
authors.lastname: Provenzano
authors.forename: Tullio
authors.initials: T
authors.lastname: Sulser
authors.forename: Silvia
authors.initials: S
authors.lastname: Behnke
authors.forename: Josefine
authors.initials: J
authors.lastname: Gerhardt
authors.forename: Ashkan
authors.initials: A
authors.lastname: Mortezavi
authors.forename: Peter
authors.initials: P
authors.lastname: Wild
authors.forename: Ferdinand
authors.initials: F
authors.lastname: Hofstädter
authors.forename: Maximilian
authors.initials: M
authors.lastname: Burger
authors.forename: Holger
authors.initials: H
authors.lastname: Moch
authors.forename: Glen
authors.initials: G
authors.lastname: Kristiansen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009376:Neoplasms, Hormone-Dependent / Q000378:metabolism* / Q000556:secondary; D011379:Prognosis; D011467:Prostate / Q000378:metabolism* / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000378:metabolism* / Q000473:pathology; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D016601:RNA-Binding Proteins / Q000378:metabolism*; D015996:Survival Rate; D046888:Tissue Array Analysis
chemical_list: C498780:IGF2BP3 protein, human; D016601:RNA-Binding Proteins